ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. The company designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
Follow-Up Questions
Who is the CEO of ProQR Therapeutics NV?
Mr. Daniel de Boer is the Chief Executive Officer of ProQR Therapeutics NV, joining the firm since 2012.
What is the price performance of PRQR stock?
The current price of PRQR is $2.19, it has decreased 0% in the last trading day.
What are the primary business themes or industries for ProQR Therapeutics NV?
ProQR Therapeutics NV belongs to Biotechnology industry and the sector is Health Care
What is ProQR Therapeutics NV market cap?
ProQR Therapeutics NV's current market cap is $230.6M
Is ProQR Therapeutics NV a buy, sell, or hold?
According to wall street analysts, 11 analysts have made analyst ratings for ProQR Therapeutics NV, including 5 strong buy, 9 buy, 1 hold, 0 sell, and 5 strong sell
